MAO-B-IN-5
MAO-B-IN-5 is a potent, selective and orally active MAO-B inhibitor with an IC50 of 0.204 µM. MAO-B-IN-5 has the potential for the research of Parkinson's disease (PD).
For research use only. We do not sell to patients.
- CAS No.: 849909-77-9
- Formula: C19H21FN2O2
- Molecular Weight:328.38
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
IC50 & Target
|
MAO-B 34.190 μM (IC50) |
MAO-A 0.204 μM (IC50) |
In Vitro
MAO-B-IN-5 (compound D0) (Sf9 cells) shows inhibitory activities towards MAO with the IC50s of 34.190 µM and 0.204 µM for MAO-A and MAO-B, respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
Pharmacokinetic Parameters of MAO-B-IN-5 in SD rats[1].
| Compound | Route | Dose (mg/kg) | Cmax (ng/mL) | AUCt (ng·h/mL) | T1/2 (h) | Vss (h) | Cl (mL/min/kg) | F (%) |
| D0 | iv | 1 | 809 | 347 | 0.37 | 1.11 | 47.1 | / |
| po | 5 | 163 | 284 | 1.27 | / | / | 16.3 |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:SD rats[1]
-
Dosage:1, 5 mg/kg
-
Administration:1 mg/kg, i.v.; 5 mg/kg, p.o.
-
Result:Showed oral bioavailability in rats (F=16.3%).
Chemical Information
-
CAS No. 849909-77-9
-
Molecular Weight 328.38
-
Formula C19H21FN2O2
-
SMILES
NC([C@@H]1CCCN1CC2=CC=C(C=C2)OCC3=CC(F)=CC=C3)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Human pluripotent stem cell midbrain dopaminergic neuron differentiation
Human pluripotent stem cells are directed toward midbrain dopaminergic neurons by first inducing a neural floor-plate-like progenitor state, then patterning cells with ventralizing SHH signaling and midbrain/WNT-FGF cues, and finally maturing progenitors into neurons expressing dopaminergic markers such as TH, NURR1/NR4A2, PITX3, DAT/SLC6A3, VMAT2/SLC18A2, GIRK2/KCNJ6, FOXA2, LMX1A, and EN1. The main readouts are loss of pluripotency, acquisition of FOXA2+/LMX1A+ midbrain floor-plate progenitors, emergence of βIII-tubulin+/MAP2+ neurons, and production of TH+ dopaminergic neurons with molecular, dopamine-release, and electrophysiological features of midbrain dopaminergic identity.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
MAO-B-IN-5 Related Classifications
HY-115986 Related Classifications
Powered by Bioz